Dr. Anna Maria Litvak, MD

Dr. Litvak practices at Cooperman Barnabas Medical Center in Livingston, New Jersey, part of RWJBarnabas Health.

Dr. Litvak's NPI, 1326319302, was assigned on January 23, 2012. Dr. Litvak graduated from Baylor College Of Medicine in 2009. Dr. Litvak holds New Jersey license 25MA09650300.

Dr. Litvak's primary practice is Cooperman Barnabas Medical Center, at 94 Old Short Hills Road, Livingston, NJ 07039 in Essex County. The practice phone is (973) 322-5000.

Dr. Litvak's primary practice is Cooperman Barnabas Medical Center in Livingston, New Jersey, part of RWJBarnabas Health. The medical group on file is RWJBarnabas Health Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Litvak practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Litvak's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Litvak is licensed in New Jersey.

CMS data shows 81 Medicare services from Dr. Litvak across 2 procedure codes in 2024, all of them office visits, for 65 Medicare patients. Medicare paid $7,674 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 65 Medicare patients who saw Dr. Litvak in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Litvak's median patient age at 68, with 92% women.

In 2024, Dr. Litvak wrote 426 Medicare Part D claims for 225 patients. 91% of them were for generic drugs. CMS names the drug for 345 of them, across 5 drugs with 11 or more claims each, at $202,025 in total drug cost. In 2023, CMS named 1,314 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Litvak for performance year 2024, reported through an alternative payment model (APM). Dr. Litvak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Litvak as offering telehealth.

Dmand AI links 2 papers to Dr. Litvak in 2019. 2019 was the busiest year, with 2. The most frequent topics are Lung Neoplasms. Dr. Litvak's most frequent co-authors are Joseph Montecalvo, MD, Natasha Rekhtman, MD, PhD and Kathryn Cecilia Arbour, MD.

Dmand AI links Dr. Litvak to 9 clinical trials, 7 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Carcinoma In Situ. Novartis Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Litvak that name 1 trial.

CMS Open Payments shows 79 general payments to Dr. Litvak from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 86% of the total. Bristol-Myers Squibb Company paid the most, $10,082. It also lists 1 research payment totaling $462 in 2021, naming 1 clinical trial.

Dr. Litvak graduated from Baylor College Of Medicine in 2009.